Cargando…

Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations

BACKGROUND: Several thousand breast cancer patients develop resistance to aromatase inhibitors (AIs) each year in the UK. Rational treatment requires an improved molecular characterisation of resistant disease. MATERIALS AND METHODS: The mutational landscape of 198 regions in 16 key breast cancer ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lopez-Knowles, Elena, Pearson, Alex, Schuster, Gene, Gellert, Pascal, Ribas, Ricardo, Yeo, Belinda, Cutts, Ros, Buus, Richard, Garcia-Murillas, Isaac, Haynes, Ben, Martin, Lesley-Ann, Smith, Ian, Turner, Nick, Dowsett, Mitch
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342946/ https://www.ncbi.nlm.nih.gov/pubmed/30563991 http://dx.doi.org/10.1038/s41416-018-0345-x

Ejemplares similares

Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition
por: López-Knowles, Elena, et al.
Publicado: (2014)

Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment
por: Schuster, Eugene F., et al.
Publicado: (2019)

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance
por: Martin, Lesley-Ann, et al.
Publicado: (2017)

ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1
por: Dunbier, Anita K., et al.
Publicado: (2011)

Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens
por: Howell, Anthony, et al.
Publicado: (2004)

Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer
por: López-Knowles, Elena, et al.
Publicado: (2015)

Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients
por: Gao, Qiong, et al.
Publicado: (2019)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study
por: Lopez-Knowles, Elena, et al.
Publicado: (2022)

De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor
por: Morel, Adeline, et al.
Publicado: (2019)

Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients
por: Allouchery, Violette, et al.
Publicado: (2018)

Characterising an aromatase inhibitor resistant breast cancer cell line
por: Harris, E, et al.
Publicado: (2012)

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?
por: Leary, A, et al.
Publicado: (2006)

Molecular response to aromatase inhibitor treatment in primary breast cancer
por: Mackay, Alan, et al.
Publicado: (2007)

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
por: Clatot, Florian, et al.
Publicado: (2016)

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
por: Buus, Richard, et al.
Publicado: (2018)

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
por: Bergamino, Milana A., et al.
Publicado: (2022)

Increased frequency of ESR1 mutation in metastatic breast cancer by dosing selective estrogen receptor modulator followed by aromatase inhibitor
por: Takeshima, Kaoru, et al.
Publicado: (2020)

Treatment of breast cancer with aromatase inhibitors--current status and future prospects.
por: LÃ¸nning, P. E., et al.
Publicado: (1989)

Aromatase inhibition in advanced prostatic cancer: preliminary communication.
por: Shearer, R. J., et al.
Publicado: (1990)

The ESR Patient Advisory Group (ESR-PAG)
Publicado: (2015)

Circulating HPV DNA as a Biomarker for Pre-Invasive and Early Invasive Cervical Cancer: A Feasibility Study
por: Bryan, Stacey J., et al.
Publicado: (2023)

Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
por: MacNeill, F. A., et al.
Publicado: (1994)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
por: Reinert, Tomás, et al.
Publicado: (2020)

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
por: Yates, R. A., et al.
Publicado: (1996)

Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor–positive breast cancers
por: Ribas, Ricardo, et al.
Publicado: (2014)

Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.
por: Davies, J. H., et al.
Publicado: (1992)

Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells.
por: Macaulay, V. M., et al.
Publicado: (1994)

ESR1 and ESR2 genotypes and the age at menarche in idiopathic scoliosis
por: Janusz, Piotr, et al.
Publicado: (2014)

Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
por: Dowsett, M., et al.
Publicado: (1991)

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.
por: Bonnefoi, H. R., et al.
Publicado: (1996)

Stochastic Cooling at the ESR
por: Beckert, Karl, et al.
Publicado: (2000)

Stochastic cooling at the ESR
por: Beckert, K, et al.
Publicado: (1999)

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)

Determination of HER2 Amplification Status on Tumour DNA by Digital PCR
por: Garcia-Murillas, Isaac, et al.
Publicado: (2013)

An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer
por: Garcia-Murillas, Isaac, et al.
Publicado: (2013)

Long-Term Effect of Aromatase Inhibition in Aromatase Excess Syndrome
por: Binder, Gerhard, et al.
Publicado: (2021)

Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation
por: Guest, Stephanie K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6jlf0l9ug0on0l8jpsn1fbmc6p